Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IONIS PHARMACEUTICALS INC Director's Dealing 2013

Apr 23, 2013

30591_dirs_2013-04-23_3cfb2b74-c1e4-4fd2-b3cb-f29233b63a10.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ISIS PHARMACEUTICALS INC (ISIS)
CIK: 0000874015
Period of Report: 2013-04-19

Reporting Person: PARSHALL B LYNNE (Director, COO, Secretary)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2013-04-19 Common Stock M 30000 $7.26 Acquired 32941 Direct
2013-04-19 Common Stock S 30000 $20.006 Disposed 2941 Direct
2013-04-22 Common Stock M 30000 $11.12 Acquired 32941 Direct
2013-04-22 Common Stock S 30000 $20.99 Disposed 2941 Direct
2013-04-23 Common Stock M 10000 $11.12 Acquired 12941 Direct
2013-04-23 Common Stock S 10000 $22.0967 Disposed 2941 Direct
2013-04-23 Common Stock M 10000 $6.81 Acquired 10000 Indirect
2013-04-23 Common Stock S 10000 $22.0967 Disposed 0 Indirect
2013-04-23 Common Stock M 10000 $6.81 Acquired 10000 Indirect
2013-04-23 Common Stock S 10000 $22.0967 Disposed 0 Indirect

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2013-04-19 Employee Stock Option (right to buy) $7.26 M 30000 Disposed 2013-09-20 Common Stock (30000) Direct
2013-04-22 Employee Stock Option (right to buy) $11.12 M 30000 Disposed 2014-01-01 Common Stock (30000) Direct
2013-04-23 Employee Stock Option (right to buy) $11.12 M 10000 Disposed 2014-01-01 Common Stock (10000) Direct
2013-04-23 Employee Stock Option (right to buy) $6.81 M 10000 Disposed 2014-01-01 Common Stock (10000) Indirect
2013-04-23 Employee Stock Option (right to buy) $6.81 M 10000 Disposed 2014-01-01 Common Stock (10000) Indirect

Footnotes

F1: Acquired as a result of exercising a stock option that was scheduled to expire on 9/20/2013. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/16/2012.

F2: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/2014. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/31/2013.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.005 to $22.16, inclusive. The reporting person undertakes to provide to Isis Pharmaceuticals, Inc., any security holder of Isis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.